SRRK (Scholar Rock Holding Corporation Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SRRK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-06 | JEFFREY S. FLIER | Director | Sell | — | — |
| 2026-07-06 | Joshua Reed | Director | Sell | — | — |
| 2026-07-06 | Katie Peng | Director | Sell | — | — |
| 2026-07-06 | Kristina Burow | Director | Sell | — | — |
| 2026-07-06 | Michael Gilman | Director | Sell | — | — |
| 2026-06-08 | SRINIVAS AKKARAJU | Director | A | — | — |
| 2026-06-08 | Michael Gilman | Director | A | — | — |
| 2026-06-08 | Kristina Burow | Director | A | — | — |
| 2026-06-08 | Richard Brudnick | Director | A | — | — |
| 2026-06-08 | JEFFREY S. FLIER | Director | A | — | — |
| 2026-06-08 | Katie Peng | Director | A | — | — |
| 2026-06-08 | Joshua Reed | Director | A | — | — |
| 2026-04-24 | Kristina Burow | Director | M | — | — |
| 2026-04-20 | Akshay Vaishnaw | President of R&D | Sell | — | — |
| 2026-04-20 | Keith Woods | Chief Operating Officer | Sell | — | — |
| 2026-04-20 | Vikas Sinha | Chief Financial Officer | Sell | — | — |
| 2026-04-20 | David Hallal | Chief Executive Officer | Sell | — | — |
| 2026-02-25 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2026-02-19 | Jing L. Marantz | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2026-02-19 | Caryn Parlavecchio | CHRO | Sell | — | — |
| 2026-02-19 | Junlin Ho | GENERAL COUNSEL | Sell | — | — |
| 2026-02-19 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2026-02-11 | Keith Woods | Chief Operating Officer | A | — | — |
| 2026-02-11 | Caryn Parlavecchio | Chief Human Resources Officer | A | — | — |
| 2026-02-11 | Junlin Ho | General Counsel | A | — | — |
| 2026-02-11 | Vikas Sinha | Chief Financial Officer | A | — | — |
| 2026-02-11 | David Hallal | Chief Executive Officer | A | — | — |
| 2026-02-11 | Mo Qatanani | Chief Scientific Officer | A | — | — |
| 2026-02-11 | Jing L. Marantz | Chief Medical Officer | A | — | — |
| 2026-02-11 | Akshay Vaishnaw | President of R&D | A | — | — |
| 2026-02-06 | Invus Global Management, LLC | 10%+ Owner | X | — | — |
| 2026-01-23 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2026-01-21 | Caryn Parlavecchio | CHRO | Sell | — | — |
| 2026-01-21 | Junlin Ho | GENERAL COUNSEL | Sell | — | — |
| 2026-01-21 | Jing L. Marantz | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2026-01-21 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2026-01-16 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2026-01-15 | Vikas Sinha | Chief Financial Officer | Sell | — | — |
| 2026-01-15 | Keith Woods | Chief Operating Officer | Sell | — | — |
| 2026-01-15 | David Hallal | Chief Executive Officer | Sell | — | — |
| 2026-01-15 | Akshay Vaishnaw | President of R&D | Sell | — | — |
| 2025-12-18 | Katie Peng | Director | Sell | — | — |
| 2025-12-16 | SRINIVAS AKKARAJU | Director | MIXED | — | — |
| 2025-12-05 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2025-10-09 | David Hallal | Chief Executive Officer | G | — | — |
| 2025-10-07 | SRINIVAS AKKARAJU | Director | Buy | — | — |
| 2025-09-24 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2025-09-17 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2025-09-17 | Katie Peng | Director | Sell | — | — |
| 2025-08-19 | Caryn Parlavecchio | CHRO | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 11,051,166 | — |
| — | 10%+ Owner | 10,825,013 | — |
| — | 10%+ Owner | 9,700,005 | — |
| — | 10%+ Owner | 9,029,044 | — |
| — | 10%+ Owner | 8,850,005 | — |
| — | 10%+ Owner | 6,788,609 | — |
| — | Director | 2,957,422 | — |
| — | 10%+ Owner | 2,676,311 | — |
| — | Director | 2,461,316 | — |
| — | Chief Executive Officer | 1,844,034 | — |
| — | Director | 1,689,555 | — |
| — | President of R&D | 630,542 | — |
| — | Chief Operating Officer | 620,055 | — |
| — | Chief Financial Officer | 619,856 | — |
| — | Director | 558,009 | — |
| — | Interim CEO and President | 480,491 | — |
| — | 10%+ Owner | 437,859 | — |
| — | CHIEF EXECUTIVE OFFICER | 425,561 | — |
| — | Chief Medical Officer | 258,496 | — |
| — | GENERAL COUNSEL | 241,545 | — |
| — | COO & CFO | 205,552 | — |
| — | CHRO | 169,087 | — |
| — | Chief Scientific Officer | 128,208 | — |
| — | CHIEF MEDICAL OFFICER | 126,012 | — |
| — | CHIEF SCIENTIFIC OFFICER | 98,645 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SRRK quote page; the site-wide leaderboard is on the insider transactions hub.